Centessa reports Q4 EPS (38c), consensus (48c)

Reports cash, cash equivalents and short-term investments of $256.5M as of December 31, 2023, which includes approximately $6.2M in net proceeds through ATM sales in Q4 ended December 31, 2023. In addition, the company received approximately $9.7M in net proceeds through ATM sales in January 2024. The company expects its cash, cash equivalents and short-term investments will fund operations into 2026, without drawing on the remaining available tranches under the Oberland credit facility. “This is an exciting and pivotal time for Centessa,” said Saurabh Saha MD PhD, CEO of Centessa. “We are laser focused on executing the PRESent registrational studies for SerpinPC, a potential first-in-class subcutaneously administered therapy with a differentiated safety profile for individuals with hemophilia B, and advancing our orexin receptor 2 agonist development program into the clinic for the treatment of narcolepsy and other sleep-wake disorders.”